-+ 0.00%
-+ 0.00%
-+ 0.00%

BE BOLD: BIMZELX® (bimekizumab-bkzx) builds on superior joint responses versus SKYRIZI® (risankizumab-rzaa) at Week 16, with clinical improvements sustained through Week 24

Barchart·11/09/2026 06:00:00
Listen to the news

ATLANTA, Nov. 9, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced Week 24 data for BIMZELX® (bimekizumab-bkzx) from BE BOLD, building on the study's previously reported Week 16 results, which demonstrated statistically significant superiority in ACR50 joint outcomes versus risankizumab at Week 16 in psoriatic arthritis (PsA).1 Numerically greater rates of ACR50 were sustained through Week 24.1 The full Week 24 findings are being presented at the 2026 ACR Convergence in Orlando, Florida, November 6–11.1 Data reported in this press release are based on the dataset included in the ACR abstract.1

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.